Arrowhead Pharmaceuticals(US:ARWR)2026-03-09 19:22Arrowhead Pharmaceuticals Conference Call Summary Company Overview - Company: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - Event: 2026 Conference at the Leerink Partners Global Healthcare Conference - Date: March 09, 2026 Key Points Pipeline Developments - SHASTA-3 and SHASTA-4: Phase 3 studies for Plozasiran in the SHTG population expected to read out in Q3 2026, with last patient visit in June [11] - Dimer/Bispecific Data: First data from a bispecific RNA molecule targeting both PCSK9 and APOC3 for mixed hyperlipidemia patients anticipated in Q3 2026 [11] - ARO-MAPT: First CNS target data expected towards the end of Q3 2026, focusing on tau reduction [12] - Obesity Targets: Updates for ARO-ALK7 and ARO-INHBE expected in the second half of 2026, with ongoing data collection [13][14] Clinical Insights - Inhibin E: Early data shows promising fat redistribution and significant liver fat reduction (76.7%) in obese diabetic patients when combined with tirzepatide [18] - ALK7: Early indications of good knockdown in fat biopsies, with further data needed to assess its potential [20] - Market Size: The clinically defined FCS market may include tens of thousands of patients with triglycerides above 880 and a history of pancreatitis or abdominal pain [25] Commercial Strategy - FCS Launch: Rapid launch with over 100 prescriptions received, including switches from competitor Ionis [24] - SHTG Market: Anticipated top-line readout in Q3 2026, with plans to file a supplemental NDA (sNDA) in Q4 2026 [27] - Pricing Strategy: Initial focus on high-risk individuals with triglycerides above 880, estimating a target population of 750,000 to 1 million [28] Regulatory Considerations - AP Risk: Improvement in acute pancreatitis (AP) risk is not necessary for U.S. regulatory approval, but may be critical in Europe [30][34] - Most-Favored-Nation Policy: Current uncertainty may affect international pricing strategies, leading to a preference for retaining control over ex-U.S. markets [46][49] Competitive Landscape - Innovation Focus: Emphasis on expanding RNAi technology beyond liver diseases to various cell types, with ongoing clinical studies in multiple areas [56][66] - Dimer Development: The potential for synergistic effects in dimer constructs, particularly with targets like APOC3 and PCSK9, is being explored [72] Future Outlook - Expansion Plans: Anticipation of new cell type access every 18-24 months, with ongoing studies in CNS and pulmonary applications [66][69] - Data Validation: Upcoming data from ARO-MAPT and bispecifics expected to validate the platform and inform future target selections [68] Additional Insights - Patient Convenience: The use of prefilled syringes for FCS and auto-injectors for SHTG is expected to enhance patient adherence [40] - Market Dynamics: Physicians are reportedly switching to Arrowhead's products due to better activity and safety profiles compared to competitors [41] This summary encapsulates the critical developments and strategic insights from Arrowhead Pharmaceuticals' conference call, highlighting the company's focus on innovation, pipeline advancements, and market positioning.